References

Comparison of Akt/mTOR signaling in primary breast tumors and matched distant metastases

10.1002/cncr.23456 · 2008 · External reference

eIF4F-mediated dysregulation of mRNA translation in cancer

10.1261/rna.080340.124 · 2025 · External reference

Molecular targeting of the oncogene eIF4E in acute myeloid leukemia (AML): A proof-of-principle clinical trial with ribavirin

10.1182/blood-2009-02-205153 · 2009 · External reference

A phase I trial of ribavirin and low-dose cytarabine for the treatment of relapsed and refractory acute myeloid leukemia with elevated eIF4E

10.3324/haematol.2014.111245 · 2015 · External reference

DNA damage and eIF4G1 in breast cancer cells reprogram translation for survival and DNA repair mRNAs

10.1073/pnas.1203853109 · 2012 · External reference

Targeting the translation machinery in cancer

10.1038/nrd4505 · 2015 · External reference

Targeting the oncogene eIF4E in cancer: From the bench to clinical trials

2011 · External reference

10.1002/bies.202300145

10.1002/bies.202300145 · 2024 · External reference

Ribavirin as an anti-cancer therapy: Acute myeloid leukemia and beyond?

10.3109/10428194.2010.496506 · 2010 · External reference

Emerging Roles of m7G-Cap Hypermethylation and Nuclear Cap-Binding Proteins in Bypassing Suppression of eIF4E-Dependent Translation

10.3390/v17030372 · 2025 · External reference

O-GlcNAc transferase activates stem-like cell potential in hepatocarcinoma through O-GlcNAcylation of eukaryotic initiation factor 4E

10.1111/jcmm.14043 · 2019 · External reference

Antitumor activity and mechanism of action of the cyclopenta[b]benzofuran, silvestrol

10.1371/journal.pone.0005223 · 2009 · External reference

CELF1 is a non-canonical eIF4E binding protein that promotes translation of epithelial-mesenchymal transition effector mRNAs

10.1093/nar/gkag123 · 2026 · External reference

Knockdown of eukaryotic translation initiation factor 4E suppresses cell growth and invasion, and induces apoptosis and cell cycle arrest in a human lung adenocarcinoma cell line

10.3892/mmr.2015.4468 · 2015 · External reference

Structure-Guided Design, Synthesis, and Evaluation of Guanine-Derived Inhibitors of the eIF4E mRNA–Cap Interaction

10.1021/jm300037x · 2012 · External reference

Abstract 1302: Targeting hormone receptor-dependent cancers with potent, selective and orally-available small molecule inhibitors of eIF4E

10.1158/1538-7445.am2019-1302 · 2019 · External reference

Integrin (alpha 6 beta 4) regulation of eIF-4E activity and VEGF translation: A survival mechanism for carcinoma cells

10.1083/jcb.200112015 · 2002 · External reference

Targets and mechanisms for the regulation of translation in malignant transformation

10.1038/sj.onc.1207544 · 2004 · External reference

Tackling the complexity of cancer with generative models

10.1016/j.cell.2026.03.027 · 2026 · External reference

Activation of p53 stimulates proteasome-dependent truncation of eIF4E-binding protein 1 (4E-BP1)

10.1042/bc20070121 · 2008 · External reference

N7-Methylguanine-Related Gene Signature Highlights EIF4E as a Novel Therapeutic Target in HER2-Negative Breast Cancer

10.1111/jcmm.70808 · 2025 · External reference

Advances in understanding and targeting eIF4E activity

10.1042/bst20241045 · 2025 · External reference

MTA2 promotes the metastasis of esophageal squamous cell carcinoma via EIF4E-Twist feedback loop

10.1111/cas.14778 · 2021 · External reference

Ribavirin as a tri-targeted antitumor repositioned drug

10.3892/or.2015.3816 · 2015 · External reference

Translational downregulation of Twist1 expression by antiproliferative gene, B-cell translocation gene 2, in the triple negative breast cancer cells

10.1038/s41419-019-1640-z · 2019 · External reference

Tumor-specific RNAi targeting eIF4E suppresses tumor growth, induces apoptosis and enhances cisplatin cytotoxicity in human breast carcinoma cells

10.1007/s10549-008-9956-x · 2009 · External reference

mTORC1-mediated cell proliferation, but not cell growth, controlled by the 4E-BPs

10.1126/science.1187532 · 2010 · External reference

Modulation of tumor eIF4E by antisense inhibition: A phase I/II translational clinical trial of ISIS 183750-an antisense oligonucleotide against eIF4E-in combination with irinotecan in solid tumors and irinotecan-refractory colorectal cancer

10.1002/ijc.30199 · 2016 · External reference

Microbiome Dynamics in Breast Cancer: Mechanisms, Therapeutic Impacts and Research gaps

10.1016/j.critrevonc.2025.104879 · 2025 · External reference

The eIF4E/eIF4G interaction inhibitor 4EGI-1 augments TRAIL-mediated apoptosis through c-FLIP Down-regulation and DR5 induction independent of inhibition of cap-dependent protein translation

10.1593/neo.10144 · 2010 · External reference

eIF4E-eIF4G complex inhibition synergistically enhances the effect of sorafenib in hepatocellular carcinoma

10.1097/cad.0000000000001074 · 2021 · External reference

Upregulation of eukaryotic translation initiation factor 4E associates with a poor prognosis in gallbladder cancer and promotes cell proliferation in vitro and in vivo

2019 · External reference

Licochalcone A inhibits EGFR signalling and translationally suppresses survivin expression in human cancer cells

10.1111/jcmm.16135 · 2021 · External reference

Oblique-incidence reflectivity difference technology identifies the antiviral drug Ribavirin as an inhibitor of lung tumor progression by targeting AMPK signaling

10.1016/j.jpha.2025.101306 · 2026 · External reference

Expression analysis and clinical significance of eIF4E, VEGF-C, E-cadherin and MMP-2 in colorectal adenocarcinoma

10.18632/oncotarget.13453 · 2016 · External reference

Synthesis and evaluation of quinazolinone derivatives as inhibitors of NF-kappaB, AP-1 mediated transcription and eIF-4E mediated translational activation: Inhibitors of multi-pathways involve in cancer

10.1016/j.ejmech.2010.04.038 · 2010 · External reference

eIF4E Activation Is Commonly Elevated in Advanced Human Prostate Cancers and Significantly Related to Reduced Patient Survival

10.1158/0008-5472.can-08-3472 · 2009 · External reference

Therapeutic suppression of translation initiation factor eIF4E expression reduces tumor growth without toxicity

10.1172/jci32044 · 2007 · External reference

Programmed cell death network in cancer drug resistance: A framework for therapeutic intervention

10.1016/j.drup.2026.101387 · 2026 · External reference

Hallmarks of cancer: New dimensions

10.1158/2159-8290.cd-21-1059 · 2022 · External reference

Hallmarks of cancer—Then and now, and beyond

10.1016/j.cell.2025.12.049 · 2026 · External reference

Translational control of the activation of transcription factor NF-κB and production of type I interferon by phosphorylation of the translation factor eIF4E

10.1038/ni.2291 · 2012 · External reference

A phase 1 dose escalation, pharmacokinetic, and pharmacodynamic evaluation of eIF-4E antisense oligonucleotide LY2275796 in patients with advanced cancer

10.1158/1078-0432.ccr-11-0430 · 2011 · External reference

Genetic dissection of the oncogenic mTOR pathway reveals druggable addiction to translational control via 4EBP-eIF4E

10.1016/j.ccr.2010.01.021 · 2010 · External reference

Oncogenic AKTivation of translation as a therapeutic target

10.1038/bjc.2011.241 · 2011 · External reference

Co-targeting hallmarks of cancer for therapeutic benefit in ovarian cancer: A scoping review

10.1016/j.ijgc.2026.104651 · 2026 · External reference

Targeting eukaryotic translation in mesothelioma cells with an eIF4E-specific antisense oligonucleotide

10.1371/journal.pone.0081669 · 2013 · External reference

Cap‐Dependent Translation Initiation Factor eIF4E: An Emerging Anticancer Drug Target

10.1002/med.21260 · 2012 · External reference

Mnk kinase pathway: Cellular functions and biological outcomes

10.4331/wjbc.v5.i3.321 · 2014 · External reference

Ribavirin suppresses eIF4E-mediated oncogenic transformation by physical mimicry of the 7-methyl guanosine mRNA cap

10.1073/pnas.0406927102 · 2004 · External reference

The histone demethylase KDM5A is required for the repression of astrocytogenesis and regulated by the translational machinery in neural progenitor cells

10.1096/fj.201700780r · 2018 · External reference

Human cytomegalovirus infection induces rapamycin-insensitive phosphorylation of downstream effectors of mTOR kinase

10.1128/jvi.78.20.11030-11039.2004 · 2004 · External reference

Eukaryotic translation initiation factor 4E induced progression of primary human mammary epithelial cells along the cancer pathway is associated with targeted translational deregulation of oncogenic drivers and inhibitors

10.1158/0008-5472.can-07-0752 · 2007 · External reference

Synergistic effects of inhibiting the MNK-eIF4E and PI3K/AKT/ mTOR pathways on cell migration in MDA-MB-231 cells

10.18632/oncotarget.24354 · 2018 · External reference

Role of eIF4E on epithelial‐mesenchymal transition, invasion, and chemoresistance of prostate cancer cells

10.1002/cac2.12011 · 2020 · External reference

Overexpression of p-Akt, p-mTOR and p-eIF4E proteins associates with metastasis and unfavorable prognosis in non-small cell lung cancer

10.1371/journal.pone.0227768 · 2020 · External reference

Identification of a first-in-class small-molecule inhibitor of the EIF4E-RBM38 complex that enhances wild-type TP53 protein translation for tumor growth suppression

10.1158/1535-7163.mct-22-0627 · 2023 · External reference

Disruption of the Rbm38-eIF4E Complex with a Synthetic Peptide Pep8 Increases p53 Expression

10.1158/0008-5472.can-18-2209 · 2019 · External reference

Phosphorylation of the proto-oncogene product eukaryotic initiation factor 4E is a common cellular response to tumor necrosis factor

10.1016/s0021-9258(18)49896-1 · 1991 · External reference

eIF4E orchestrates mRNA processing, RNA export and translation to modify specific protein production

10.1080/19491034.2024.2360196 · 2024 · External reference

HIF-1α pathway: Role, regulation and intervention for cancer therapy

10.1016/j.apsb.2015.05.007 · 2015 · External reference

Therapeutic targeting of the eIF4E cap-binding domain reveals control of lineage fate in prostate cancer

10.1172/jci199838 · 2026 · External reference

Small-molecule inhibition of the interaction between the translation initiation factors eIF4E and eIF4G

10.1016/j.cell.2006.11.046 · 2007 · External reference

Translation initiation and its relationship with metabolic mechanisms in cancer development, progression and chemoresistance

10.1016/bs.apcsb.2022.05.011 · 2022 · External reference

COX-2 expression in dysplasia of the head and neck: Correlation with elF4E

10.1002/1097-0142(20011001)92:7<1888::aid-cncr1706>3.0.co;2-z · 2001 · External reference

Chemical Probes for Studying the Eukaryotic Translation Initiation Factor 4E (eIF4E)-Regulated Translatome in Cancer

10.1021/acsptsci.4c00674 · 2025 · External reference

Apoptosis induced by the kinase inhibitor BAY 43-9006 in human leukemia cells involves down-regulation of Mcl-1 through inhibition of translation

10.1074/jbc.m506551200 · 2005 · External reference

The multikinase inhibitor sorafenib induces apoptosis in highly imatinib mesylate-resistant bcr/abl+ human leukemia cells in association with signal transducer and activator of transcription 5 inhibition and myeloid cell leukemia-1 down-regulation

10.1124/mol.106.033308 · 2007 · External reference

Phosphorylation of eIF4E promotes EMT and metastasis via translational control of SNAIL and MMP-3

10.1038/onc.2014.146 · 2015 · External reference

The role of translation in neoplastic transformation from a pathologist’s point of view

10.1038/sj.onc.1207552 · 2004 · External reference

The Bi-steric, mTORC1-Selective Inhibitor, RMC-5552, in Advanced Solid Tumors: A Phase 1 Trial

10.1158/1078-0432.ccr-25-2112 · 2025 · External reference

Differential expression of vascular endothelial growth factor mRNA vs protein isoform expression in human breast cancer and relationship to eIF-4E

10.1038/bjc.1998.356 · 1998 · External reference

Human Merkel cell polyomavirus small T antigen is an oncoprotein targeting the 4E-BP1 translation regulator

10.1172/jci46323 · 2011 · External reference

Cancer in 4D: Toward Spatiotemporal Hallmark Ecosystems

10.1016/j.trecan.2026.01.004 · 2026 · External reference

Signalling to eIF4E in cancer

10.1042/bst20150126 · 2015 · External reference

Translational control in cancer

10.1038/nrc2824 · 2010 · External reference

LMP1 promotes nasal NK/T-cell lymphoma cell function by eIF4E via NF-κB pathway

10.3892/or.2015.4305 · 2015 · External reference

Fine-tuning p53 activity by modulating the interaction between eukaryotic translation initiation factor eIF4E and RNA-binding protein RBM38

2021 · External reference

eIF4E-Overexpression imparts perillyl alcohol and rapamycin-mediated regulation of telomerase reverse transcriptase

10.1016/j.yexcr.2013.05.029 · 2013 · External reference

Inhibition of Myc-dependent apoptosis by eukaryotic translation initiation factor 4E requires cyclin D1

10.1038/sj.onc.1203446 · 2000 · External reference

Inhibition of eIF4E signaling by ribavirin selectively targets lung cancer and angiogenesis

10.1016/j.bbrc.2020.05.127 · 2020 · External reference

Ribavirin augments doxorubicin’s efficacy in human hepatocellular carcinoma through inhibiting doxorubicin-induced eIF4E activation

10.1002/jbt.22007 · 2018 · External reference

Ribavirin targets eIF4E dependent Akt survival signaling

10.1016/j.bbrc.2008.07.163 · 2008 · External reference

Translation control during prolonged mTORC1 inhibition mediated by 4E-BP3

10.1038/ncomms11776 · 2016 · External reference

The hallmarks of oncogenic signaling: From pathways to resistance in cancer therapy

10.1016/j.drup.2026.101355 · 2026 · External reference

PI3K/Akt/mTOR pathway expression profiling reveals age- and subtype-specific molecular heterogeneity in the Nigerian breast cancer landscape

2026 · External reference

Discovery of Potent and Selective MNK Kinase Inhibitors for the Treatment of Leukemia

10.1021/acs.jmedchem.4c03158 · 2025 · External reference

eIF4F controls ERK MAPK signaling in melanomas with BRAF and NRAS mutations

2024 · External reference

Targeting eIF4E inhibits growth, survival and angiogenesis in retinoblastoma and enhances efficacy of chemotherapy

10.1016/j.biopha.2017.10.034 · 2017 · External reference

Overexpression of eukaryotic initiation factor 4E (eIF4E) and its clinical significance in lung adenocarcinoma

10.1016/j.lungcan.2009.02.001 · 2009 · External reference

4EGI-1 induces apoptosis and enhances radiotherapy sensitivity in nasopharyngeal carcinoma cells via DR5 induction on 4E-BP1 dephosphorylation

10.18632/oncotarget.7824 · 2016 · External reference

4E-BP1 Is a Tumor Suppressor Protein Reactivated by mTOR Inhibition in Head and Neck Cancer

10.1158/0008-5472.can-18-1220 · 2019 · External reference

CGP57380 enhances efficacy of RAD001 in non-small cell lung cancer through abrogating mTOR inhibition-induced phosphorylation of eIF4E and activating mitochondrial apoptotic pathway

10.18632/oncotarget.8497 · 2016 · External reference

The role of MNK proteins and eIF4E phosphorylation in breast cancer cell proliferation and survival

10.4161/cbt.10.7.12965 · 2010 · External reference

Update on the Development of MNK Inhibitors as Therapeutic Agents

10.1021/acs.jmedchem.1c00368 · 2022 · External reference

The Translational Regulation in mTOR Pathway

10.3390/biom12060802 · 2022 · External reference

Contribution of eIF-4E inhibition to the expression and activity of heparanase in human colon adenocarcinoma cell line: LS-174T

10.3748/wjg.v9.i8.1707 · 2003 · External reference

Effects of simian virus 40 large and small tumor antigens on mammalian target of rapamycin signaling: Small tumor antigen mediates hypophosphorylation of eIF4E-binding protein 1 late in infection

10.1128/jvi.79.11.6882-6889.2005 · 2005 · External reference

MNK1/2 inhibition limits oncogenicity and metastasis of KIT-mutant melanoma

10.1172/jci91258 · 2017 · External reference

Eukaryotic initiation factor 4E (eIF4E) and angiogenesis: Prognostic markers for breast cancer

10.1186/1471-2407-6-231 · 2006 · External reference

The mechanism of the PI3K-AKT-mTOR signaling pathway in renal cell carcinoma: Current developments and future prospects

10.3389/fonc.2026.1745024 · 2026 · External reference